Insmed Incorporated (NASDAQ:INSM) CFO Sells $5,148,105.92 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 57,766 shares of the firm's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $89.12, for a total value of $5,148,105.92. Following the sale, the chief financial officer now directly owns 103,412 shares of the company's stock, valued at approximately $9,216,077.44. This represents a 35.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, June 3rd, Sara Bonstein sold 1,579 shares of Insmed stock. The stock was sold at an average price of $71.50, for a total value of $112,898.50.
• On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total value of $107,206.74.
• On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total value of $601,474.70.

Insmed Stock Up 1.9%

NASDAQ INSM traded up $1.85 during trading on Friday, hitting $98.73. 5,318,455 shares of the company traded hands, compared to its average volume of 2,164,284. Insmed Incorporated has a 12 month low of $60.40 and a 12 month high of $100.00. The business has a fifty day simple moving average of $71.41 and a 200 day simple moving average of $73.61. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $17.98 billion, a P/E ratio of -17.66 and a beta of 0.80.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same quarter last year, the business earned ($1.06) earnings per share. Insmed's quarterly revenue was up 22.9% on a year-over-year basis. As a group, sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on INSM. UBS Group decreased their target price on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Bank of America raised their target price on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday. HC Wainwright raised their target price on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Insmed in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insmed has an average rating of "Moderate Buy" and an average target price of $104.81.

Hedge Funds Weigh In On Insmed

A number of institutional investors have recently made changes to their positions in the business. Strs Ohio bought a new position in shares of Insmed in the first quarter worth about $1,961,000. Intech Investment Management LLC boosted its holdings in Insmed by 43.2% during the first quarter. Intech Investment Management LLC now owns 101,979 shares of the biopharmaceutical company's stock valued at $7,780,000 after purchasing an additional 30,752 shares in the last quarter. Bayforest Capital Ltd boosted its holdings in Insmed by 255.0% during the first quarter. Bayforest Capital Ltd now owns 7,054 shares of the biopharmaceutical company's stock valued at $538,000 after purchasing an additional 5,067 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Insmed by 10.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company's stock valued at $41,157,000 after purchasing an additional 52,637 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in Insmed by 53.3% during the first quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company's stock valued at $18,979,000 after purchasing an additional 86,540 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.